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compared to salmeterol/fluticasone in
COPD: FLAME-based modelling in a
Swedish population
Leif Bjermer1, Job F. M. van Boven2,3, Madlaina Costa-Scharplatz4, Dorothy L. Keininger5, Florian S. Gutzwiller5,
Karin Lisspers6, Ronan Mahon7, Petter Olsson4 and Nicolas Roche8*
Abstract
Background: This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/
fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow
limitation and ≥1 exacerbation in the preceding year.
Methods: A previously published and validated patient-level simulation model was adapted using clinical data
from the FLAME trial and real-world cost data from the ARCTIC study. Costs (total monetary costs comprising drug,
maintenance, exacerbation, and pneumonia costs) and health outcomes (life-years (LYs), quality-adjusted life-years
(QALYs)) were projected over various time horizons (1, 5, 10 years, and lifetime) from the Swedish payer’s
perspective and were discounted at 3% annually. Uncertainty in model input values was studied through one-way
and probabilistic sensitivity analyses. Subgroup analyses were also performed.
Results: IND/GLY was associated with lower costs and better outcomes compared with SFC over all the analysed
time horizons. Use of IND/GLY resulted in additional 0.192 LYs and 0.134 QALYs with cost savings of €1211
compared with SFC over lifetime. The net monetary benefit (NMB) was estimated to be €8560 based on a
willingness-to-pay threshold of €55,000/QALY. The NMB was higher in the following subgroups: severe (GOLD 3),
high risk and more symptoms (GOLD D), females, and current smokers.
Conclusion: IND/GLY is a cost-effective treatment compared with SFC in COPD patients with mMRC dyspnea
grade ≥ 2, moderate to very severe airflow limitation, and ≥1 exacerbation in the preceding year.
Keywords: Chronic obstructive pulmonary disease, Indacaterol/glycopyrronium, Cost-effective, Exacerbation
Summary
Indacaterol/glycopyrronium is more effective and cost
saving vs salmeterol/fluticasone in Swedish COPD patients
with a history of exacerbations.
Background
Chronic obstructive pulmonary disease (COPD) is a pre-
ventable and treatable disease characterised by persistent
respiratory symptoms and airflow limitation and is a
major cause of morbidity and mortality throughout the
world [1–4]. In the European Union, the total direct and
indirect cost for COPD amounts to nearly €48 billion
[5]. In Sweden, the prevalence of COPD was reported to
be 16.2%; 6.8% men and 6.6% women aged ≥40 years
had spirometric stage II and higher COPD [6]. The
societal costs of COPD in Sweden are high, with total
annual costs estimated to be €1.5 bn (SEK 13.9 bn) in
2010, where 35% accounted for direct costs and 65% for
indirect costs [7]. A survey reported that subjects with
moderate and severe/very severe COPD accounted for
37% and 3% of the studied population (subjects with
* Correspondence: nicolas.roche@aphp.fr
8Respiratory and Intensive Care Medicine, Cochin Hospital (AP-HP) and
University Paris Descartes, Paris, France
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bjermer et al. Respiratory Research  (2017) 18:206 
DOI 10.1186/s12931-017-0688-5
COPD aged 39–84 years living in northern Sweden), but
contributed to 80% of the total COPD costs in Sweden
(66% and 14%, respectively) [7].
According to the international Global Initiative for
Chronic Obstructive Lung Disease (GOLD) report,
COPD treatment aims to reduce exacerbations and
improve quality of life [1]. For that purpose, besides
non-pharmacologic treatments, several medications are
available including bronchodilators and inhaled cortico-
steroids. The 2017 GOLD report recommends the first
line use of dual bronchodilators, such as combination
of the long-acting β2-adrenergic agonist (LABA) inda-
caterol and the long-acting muscarinic antagonist
(LAMA) glycopyrronium (IND/GLY), in the treatment
of symptomatic COPD patients, regardless of their
exacerbation risk [1]. In contrast, the use of inhaled
corticosteroid (ICS)-containing combination therapies,
such as salmeterol/fluticasone (SFC) may only be a first
choice therapy in COPD patients with features of
asthma [1]. Key evidence for this recent GOLD strategy
comes from the FLAME trial which demonstrated the
superiority of IND/GLY in significantly reducing the
rate of moderate or severe COPD exacerbations by 17%
vs salmeterol/fluticasone (SFC) and increasing time-to-
first moderate or severe exacerbation in patients with dys-
pnoea modified Medical Research Council (mMRC) scale
grade ≥ 2 and a documented history of ≥1 moderate or se-
vere COPD exacerbations during the previous year [8]. In
addition, the incidence of pneumonia was significantly
lower in patients on IND/GLY than in those on SFC
(3.2% vs. 4.8%, p = 0.02). This, along with the results
demonstrated in the ILLUMINATE and LANTERN
trial, indicates that IND/GLY addresses needs for both
exacerbating and non-exacerbating patients, with a lower
risk of pneumonia (the clinical significance of reduced in-
cidence of pneumonia remains to be elucidated) than ICS-
containing regimens [9, 10].
The Swedish health care system is financed by a so-
cial insurance that provides all citizens with subsidised
healthcare through the government. For prescribed
drugs fees to the user are capped at 2200 Swedish
Krona (SEK) or around €230 per annum. The dual
bronchodilator IND/GLY is approved and reimbursed
in Sweden for the maintenance treatment for COPD
patients remaining symptomatic on long-acting bron-
chodilator monotherapy [11].
Because COPD carries a significant health and eco-
nomic burden, available therapies should be critically
evaluated for their costs and benefits when making
treatment decisions. Indeed, two previously conducted
cost-effectiveness analyses (CEAs) have shown favourable
cost-effectiveness of IND/GLY compared with SFC in pa-
tients with moderate-to-severe COPD and a history of
one or no exacerbation in the previous year [12, 13].
Given changing drug treatment costs and the growing role
of LABA/LAMAs in the GOLD 2017 strategy new eco-
nomic evaluations are needed.
This analysis therefore aimed to determine the health
economic impact of IND/GLY and SFC as competing
treatment options in COPD patients with moderate to
very severe airflow limitation and a history of ≥1 exacer-
bation in the preceding year.
Methods
Study design
A previously published and validated microsimulation
model [14], was employed to assess the cost-effectiveness
(a type of economic evaluation that compares relative
costs and outcomes of two or more treatments) of IND/
GLY compared with SFC, and was adapted for the present
analysis by incorporating clinical data from the FLAME
study and real-world Swedish cost data.
Perspective
The analysis was conducted from a Swedish payer’s
perspective. Only direct costs were considered for the
analysis.
Patient population
The FLAME study was a 52-week, phase IIIB, multi-
centre, randomised, double-blind, double-dummy,
parallel-group, non-inferiority trial that included adults
aged ≥40 years, with a clinical diagnosis of COPD, with
a mMRC score ≥ 2, a post-bronchodilator forced ex-
piratory volume in 1 s (FEV1) of ≥25% predicted to
<60% predicted, and a post-bronchodilator ratio of
FEV1 to forced vital capacity (FVC) of <0.70 [8]. In
addition, patients had a documented history of ≥1
COPD exacerbation during the previous year for which
they had received treatment with systemic glucocorticoids,
antibiotic agents, or both. Table 1 represents the baseline
characteristics of the FLAME study population.
Model structure
A patient-level simulation model was chosen over a co-
hort model because it is better suited to simultaneously
account for different aspects of a patient’s profile such as
smoking status, GOLD FEV1 status and exacerbation
history, and it better reflects the heterogeneous disease
progression in COPD patients [15]. Figure 1 shows the
structure of the model. In-depth model mechanics and
validation have been previously published and the model
has been used in an earlier assessment of dual broncho-
dilation by IND/GLY [12–14]. This model was adapted
to the Swedish setting using exacerbation and mainten-
ance costs from the ARCTIC study, a large, real-world
retrospective Swedish cohort study of 18,586 eligible pri-
mary care COPD patients [16–18]. Other inputs such as
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costs data, utilities and mortality data were derived from
publicly available sources to compare IND/GLY with
SFC.
Disease progression
A simulated cohort of 100,000 patients was assigned
baseline characteristics derived from the FLAME trial.
The model then generated patients based on the mean
values and variance-covariance matrices derived from
patient-level trial data. In the simulation, a generated
patient moved through the model in cycles of 6 months,
experiencing disease progression and clinical events
based on their characteristics and pre-defined probabil-
ities of experiencing events until death or the end of
the time horizon. These clinical events included FEV1
decline, exacerbations and pneumonia events. A disease
severity level was estimated at each cycle. The patient’s
disease status was represented by their percent pre-
dicted FEV1 score, which was generated for each pa-
tient according to their baseline characteristics.
Treatment-specific FEV1 improvements as reported in
the FLAME trial were added to each treatment group.
Increase over baseline FEV1 was assumed to be main-
tained over time. The patient’s FEV1 declined over time
at a rate described for the general population studied
by Falaschetti et al. [19]. As FEV1 declines, patients
Table 1 FLAME patient population baseline characteristics
Baseline characteristics Values
Age at baseline, mean (SD), years 64.6 (7.8)
Height, mean (SD), cm 169 (8.7)
Weight, mean (SD), kg 73.9 (17.1)
BMI, mean (SD), kg/m2 25.9 (5.2)
Proportion males, n (%) 2557 (76.1)
Severity of COPD
GOLD 1a, n (%) 0 (0.0)
GOLD 2a, n (%) 1123 (33.7)
GOLD 3a, n (%) 1954 (58.6)
GOLD 4a, n (%) 257 (7.7)
Group Ab, n (%) 2 (0.1)
Group Bb, n (%) 822 (24.4)
Group Cb, n (%) 3 (0.1)
Group Db, n (%) 2514 (74.8)
Number of COPD exacerbations in the previous year 1.19
Current smokers, n (%) 1333 (39.6)
BMI body mass index, COPD chronic obstructive pulmonary disease, GOLD
global initiative for chronic obstructive lung disease, SD standard deviation
aSeverity of airflow limitation based on 2011–2014 GOLD criteria; bBased on
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• Risk of exacerbations for IND/GLY  
• Exacerbation rate ratio of SFC vs
IND/GLY 
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• Drug cost 
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Estimate costs & QALYs
Fig. 1 Model structure. Figure notes: BMI: body mass index; FEV1: forced expiratory volume in 1 s; ICER: incremental cost-effectiveness ratio; ICUR:
incremental cost-utility ratio; IND/GLY: indacaterol/glycopyrronium; NNT: number needed to treat; QALY: quality-adjusted life-year;
SFC: salmeterol/fluticasone
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move into GOLD airflow limitation stages of increasing
severity.
Exacerbations and pneumonia
An annualised rate of moderate and severe exacerba-
tions adjusted for cycle length was applied, with a prob-
ability that a patient experienced either a moderate or
severe exacerbation at each cycle (proportion calcula-
tion based on number of exacerbations/ total exacerba-
tions as reported in the FLAME study). Though the
FLAME study assessed all exacerbations including mild
exacerbations, the present analyses only focused on
moderate and severe exacerbations (see Additional file
1 for definitions). Pneumonia incidence rates and costs
were calculated considering inclusion of an ICS com-
parator and the established evidence of risk of pneumo-
nia with ICS use [20].
Time horizon
Cumulative costs and health outcomes for both IND/
GLY and SFC were estimated using a lifetime horizon
(considered to be 78 years when ~100% patients are
dead) according to Swedish guidelines [21]. Treatment
effects were assumed to be constant over the lifetime
horizon. To better inform healthcare policies on the
short-term, different time horizons (1, 5 and 10 years)
were used in the scenario analyses.
Model input parameters
Efficacy
The efficacy inputs used in the analysis were derived from
the FLAME trial for the modified intention-to-treat popu-
lation (Table 2). The FLAME trial demonstrated superior
efficacy of IND/GLY over SFC in reducing the annual rate
of moderate and severe exacerbations, improvement in
Table 2 Model inputs
Parameter Mean Variance Source
Clinical efficacy
Annual rate of moderate and severe exacerbations IND/GLY 0.98 CI: 0.88—1.1 [8]
Annual rate of moderate and severe exacerbations SFC 1.19 CI: 1.07—1.32 [8]
LS mean improvement in pre-dose trough FEV1 from baseline
in litres at 52 weeks IND/GLY
0.015 CI: 0.000—0.030 [8]
LS mean improvement in pre-dose trough FEV1 from baseline
in litres at 52 weeks SFC
−0.048 CI: −0.063—(−0.033) [8]
Pneumonia incidence rate IND/GLY 0.035 CI: 0.026—0.044 [8]
Pneumonia incidence rate SFC 0.054 CI: 0.042—0.066 [8]
Costs (€)
Drug costs (per day) IND/GLY 1.50 CI: 1.32—2.19 [22]
Drug costs (per day) SFC 1.43 CI: 1.25—2.08 [22]
Moderate exacerbation cost per occurrence
Moderate airflow limitation
544 (median: 197) SD: 893 [16]
Moderate exacerbation cost per occurrence
Severe airflow limitation
530 (median: 221) SD: 712 [16]
Moderate exacerbation cost per occurrence
Very severe airflow limitation
481 (median: 219) SD: 705 [16]
Severe exacerbation cost per occurrence
Moderate airflow limitation
5168 (median: 3616) SD: 5282 [16]
Severe exacerbation cost per occurrence
Severe airflow limitation
5172 (median: 3959) SD: 5136 [16]
Severe exacerbation cost per occurrence
Very severe airflow limitation
7180 (median: 4584) SD: 7706 [16]
Annual non-exacerbation related maintenance costs
Moderate airflow limitation
5936 – [16]
Annual non-exacerbation related maintenance costs
Severe airflow limitation
5760 – [16]
Annual non-exacerbation related maintenance costs
Very severe airflow limitation
6493 – [16]
Pneumonia costs 4822 – [23]
Costs (€) were inflated to the year 2015
CI confidence interval, FEV1 forced expiratory volume in 1 s, GOLD global initiative for chronic obstructive lung disease, IND/GLY indacaterol/glycopyrronium, LS
least squares, SD standard deviation, SFC salmeterol/fluticasone
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trough FEV1, health-related quality-of-life, and decrease in
the use of rescue medication [8]. Definitions of exacerba-
tion and pneumonia are provided in the Additional file 1.
The annualised rates of pneumonia-related events
were derived from the incidence of pneumonia reported
at 52 weeks and the total number of treatment years in
the FLAME study by the following equation (Table 2).
Annualized rate = number of events/person years, where
person years = ~N/2.
Costs
The cost items considered were drugs for COPD treat-
ment, maintenance/monitoring, exacerbations (moderate
and severe) and pneumonia events. Daily drug costs were
derived from the Swedish Pharmaceutical Benefits Agency
(TLV) [22]. Table 2 shows the drug costs (per day) used in
the analysis. Both maintenance and exacerbation costs
were sourced from a burden of illness analysis in the
ARCTIC study (Table 2) [16]. The cost inputs used and
their definitions are provided in the Additional file 1.
Moderate exacerbation costs comprised the following
costs during 14 days after the exacerbation occurrence:
outpatient visits, nurse visits, physician visits, oral steroids,
and antibiotics targeted at respiratory diseases [16]. Mod-
erate exacerbation costs are low and independent of the
severity of airflow limitation. Severe exacerbation costs
comprised all the components of moderate exacerbation
costs and costs of hospital admissions [16]. There may be
outpatient costs in patients hospitalized for exacerbations,
corresponding to healthcare expenses occurring between
discharge and day 14 after exacerbation onset.
Maintenance costs were defined as non-exacerbation
related cost after the exclusion of COPD drug costs [16].
Pneumonia costs were based on three diagnosis-related
group (DRG) codes (D47A, D47C and D47E) describing
lung inflammation with three levels of complications [23].
As no case mix information was available, an average of
all three was assumed (Table 2). Costs were inflated to the
year 2015 where necessary using the Harmonized Indices
of Consumer Prices [24] and are expressed in 2015 euros
(€) using European Central Bank foreign exchange refer-
ence rates (2015 annual average SEK/€ rate, 9.35:1 or
1:0.107) [25].
Utilities
Utilities, which represent the strength of a society’s
preference for specific health-related outcomes, were
calculated at the end of each cycle depending on disease
severity status and other characteristics, based on a
regression model by Rutten-van Mölken et al. [26] (see
Additional file 1). The co-variate values were informed
by the characteristics of simulated patients in the model.
Baseline characteristics, including gender, body mass
index etc. were derived from the FLAME trial baseline
data [8]. FEV1% predicted over the time horizon of the
model is described under disease progression. ER visits
and hospitalisation admissions were linked to the inci-
dence of moderate exacerbations and severe exacerba-
tions, respectively, predicted by the model for each
comparator.
Both costs and health benefits were discounted annually
at the rate of 3% according to Swedish guidelines [27].
Mortality
Swedish life tables from Statistics Sweden for 2015 were
used to generate background all-cause mortality [28].
Overall mortality was calculated by applying a COPD
specific hazard ratio of 1.02 based on the Obstructive
Lung Disease in Northern Sweden COPD study [29].
Supplementary details can be found in the Additional
file 1. This hazard ratio was adjusted by the predicted
decline in FEV1 for an individual patient, using the fol-
lowing equation:
Probability of death = (general population risk for the
appropriate age and gender) * 1.02^ (the decline in FEV1
percent predicted).
Exacerbations themselves, in fact, did not affect mor-
tality in this model. Both the rate of exacerbations and
COPD-related mortality rate were based upon FEV1
status.
Model outputs
The model outputs analysed in terms of health benefit
were: life-years (LYs) and quality-adjusted life-years
(QALYs). QALYs were calculated as a product of the
quantity (LYs) and quality (utilities) of life lived. The
model output in terms of cost was the total monetary
cost which comprised drug, maintenance, exacerbation,
and pneumonia costs. Net monetary benefit (NMB) was
also estimated using the following formula [30]: NMB
= (WTP*ΔE) - ΔC, where WTP is the willingness to pay
(per QALY) threshold, ΔE is the difference in effective-
ness (e.g. number of QALYs) and ΔC is the difference
in costs. NMB >0 would indicate that IND/GLY was
cost-effective at the given WTP threshold.
Number needed to treat (NNT), which represents the
average number of patients who need to be treated to
prevent one patient from having an exacerbation was es-
timated for exacerbations. NNTs were calculated based
on the following equation:
NNT = 1/ ((proportion benefiting from an interven-
tion)-(proportion benefiting from a control)).
The NNT to prevent one severe exacerbation and one
case of repeat exacerbation were also calculated and data
are presented in the Additional file 1.
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Sensitivity analyses
Both one-way sensitivity analyses and probabilistic sen-
sitivity analyses (PSA) were performed to acknowledge
the uncertainty of key model input values and to test
the robustness of the results.
One-way sensitivity analyses were conducted by
changing each model input value discretely by 25%,
keeping other model input values constant to identify
key parameters affecting the results. The model inputs
studied in the one-way sensitivity analyses were: exacer-
bation rate ratio, exacerbation severity, drug costs,
FEV1 benefit, exacerbation costs, baseline rate of exac-
erbations, maintenance costs, pneumonia costs, and
discount rates (0, 2.5, 3.5, 4, 5, 7, and 10%, for both
costs and effects).
Details of the PSA can be found in the Additional file 1.
Subgroup analyses
Subgroup analyses were also performed with respect to
smoking (yes vs no), severity status (severity of airflow
limitation (GOLD stages 1, 2, 3 and 4), and GOLD
2015-A, B, C and D categories based on symptoms, air-




IND/GLY was associated with lower costs and better
outcomes compared with SFC over all the analysed time
horizons of 1, 5, 10 years and lifetime. Compared with
SFC, treatment with IND/GLY resulted in the addition
of 0.192 LYs and 0.134 QALYs as well as cost savings of
€1211 per patient over lifetime. Table 3 presents the re-
sults for the other time horizons (1, 5, and 10 years). As
compared to the findings at 1 year, greater cost savings
and more benefits were observed at the extended time
horizons.
Fewer moderate and severe exacerbations were re-
ported with the use of IND/GLY compared with SFC
over all the time horizons (Table 4). Since severe exacer-
bations are defined as those requiring hospitalization
in addition to treatment with systemic corticosteroids
and/or antibiotics, the results imply that hospitalization
rates tend to be lower with IND/GLY compared with SFC.
Furthermore, the incidence of pneumonia was lower
among patients receiving IND/GLY compared to those
receiving SFC over the lifetime horizon (0.39 vs. 0.58).
The NMB was estimated to be €8560 based on a WTP
threshold of €55,000/QALY.
The NNT to prevent one moderate or severe exacer-
bation was estimated to be 5 (4.76), i.e., for every ~5 pa-
tients treated over 12 months with IND/GLY rather than
SFC, on average, one exacerbation was avoided. Or, in
other words, if ~5 patients with moderate to very severe
airflow limitation and ≥1 exacerbation in the preceding
year are treated with IND/GLY instead of SFC, one ex-
acerbation can be prevented.
Uncertainty analyses
NMB was also positive after variation in the values of
the following parameters: SFC exacerbation rate (1.07,
1.30), SFC cost per day (1.25, 2.08), IND/GLY FEV1
benefit (0.00, 0.03), exacerbation costs (25% variation)
Table 3 Incremental results for the base case cost-effectiveness







1 0.617 0.615 0.002
5 2.513 2.495 0.018
10 4.102 4.054 0.047
Lifetime 5.653 5.520 0.134
LYs (per
patient)
1 0.979 0.979 0.000
5 4.132 4.117 0.015
10 6.780 6.726 0.055
Lifetime 9.328 9.137 0.192
Total costs (€)
(per patient)a
1 5406 5621 −214
5 29,486 30,620 −1134
10 50,062 51,716 −1654
Lifetime 68,406 69,618 −1211
IND/GLY indacaterol/glycopyrronium, LYs life-years, QALYs quality-adjusted life-
years, SFC salmeterol/fluticasone
aNegative numbers indicate cost savings (e.g., IND/GLY results in savings of
€1654 per patient over a time horizon of 10 years compared to SFC)
Table 4 Number of exacerbations over the time horizons
Time horizon (years) IND/GLY SFC Incremental
All exacerbations (moderate and severe)
1 year 0.57 0.68 −0.11
5 years 3.26 3.92 −0.66
10 years 5.83 6.96 −1.13
Lifetime 8.62 10.09 −1.48
Moderate exacerbations
1 year 0.47 0.57 −0.11
5 years 2.73 3.27 −0.55
10 years 4.87 5.81 −0.94
Lifetime 7.20 8.44 −1.24
Severe exacerbations
1 year 0.09 0.11 −0.02
5 years 0.54 0.65 −0.11
10 years 0.96 1.15 −0.18
Lifetime 1.41 1.66 −0.24
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and pneumonia costs (25% variation) (Fig. 2) and when
different discount rates were applied (data not shown).
This indicates IND/GLY continues to be cost-effective
under each of these alternative scenarios.
Results for the PSA are presented in the Additional file 1.
Subgroup analyses
At a WTP threshold of €55,000/QALY and considering
the variables- severity, gender and smoking status, the
NMB increased further in the following subgroups: se-
vere (GOLD 3, 2011–2014 criteria), high risk and more
symptoms (GOLD D, 2015 criteria), female gender, and
current smokers (Fig. 3).
Discussion
Results of this analysis indicated that IND/GLY is cost
saving with respect to reduction in exacerbation and
pneumonia costs, and associated with favourable clin-
ical effects such as reduced rate of moderate and severe
exacerbations and lower incidence of pneumonia com-
pared with SFC. These results were robust in uncer-
tainty analyses. With various time horizons assessed,
both immediate and lifelong benefits were observed
with IND/GLY over SFC implying the beneficial use of
IND/GLY for short-term or long-term policy planning.
To highlight, the decrease in cost savings from 10 years
to lifetime was due to increasing maintenance costs. At
10 years, IND/GLY is delaying transition to GOLD state
IV and therefore is saving cost, but by lifetime almost
all patients (who don’t die of comorbidities or other
reasons) progress to GOLD IV so the cumulative savings
in maintenance costs is less pronounced. Hence, greater
drug costs for IND/GLY over this more distal time
period results in overall costs being slightly higher for
IND/GLY compared to SFC. Results from the pre-
specified subgroup analyses also suggest that even in
much targeted use, IND/GLY is the preferable treat-
ment option compared to SFC.
Results of this study are in line with the previously
conducted CEA in the Swedish setting, which suggested
that IND/GLY is associated with cost savings and is
more effective than SFC in moderate to severe COPD
patients with no history of exacerbations [13]. Recent
studies have also demonstrated cost-effectiveness of dual
bronchodilators over monotherapies in patients with
COPD [31, 32].
To the best of our knowledge, this is the first study to
assess the cost-effectiveness of IND/GLY versus SFC uti-
lising clinical data from the FLAME trial, which assessed
COPD patients with moderate to very severe airflow
limitation and ≥1 exacerbation in the preceding year.
Results from the present analyses become more relevant
with the recent recommendations from GOLD suggest-
ing the first-line option of dual bronchodilators in many
symptomatic COPD patients, regardless of their exacer-
bation risk. The subgroup analyses highlight specific
populations in which IND/GLY can be an economic
advantage over the use of SFC in settings with restrained
budgets. The current analysis not only focused on the
cost-effectiveness outcomes, but also on outcomes rele-
vant for clinical practice such as exacerbations, pneumo-
nia and NNT.
6,500 7,000 7,500 8,000 8,500 9,000 9,500 10,000 10,500
SFC exacerbation rate (1.07, 1.30)
IND/GLY exacerbation rate (0.88, 1.10)
IND/GLY drug cost per day (1.32, 2.19)
SFC drug cost per day (1.25, 2.08)
SFC FEV1 benefit (-0.063, -0.033)
IND/GLY FEV1 benefit (0.00, 0.03)
Exacerbation costs differ by 25%
Pneumonia costs differ by 25%
Maintenance costs differ by 25%
NMB ( 55,000 per QALY) 
Upper Value Tested
Lower Value Tested
Fig. 2 Net monetary benefit for the sensitivity analysis. Figure notes: FEV1: forced expiratory volume in 1 s; IND/GLY: indacaterol/glycopyrronium;
NMB: net monetary benefit; QALY: quality-adjusted life-year
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There are also several limitations to this study.
Results from this analysis are relevant to patients re-
sembling the studied population in the FLAME trial i.e.
COPD patients with mMRC dyspnea grade ≥ 2, moder-
ate to very severe airflow limitation and ≥1 exacerba-
tion in the preceding year. We can only speculate that
inhaler technique and lower adherence in real-life pa-
tients as compared to a clinical trial population would
influence treatment effectiveness in a similar way for all
maintenance treatments, hence not affecting differences
between them; however, we acknowledge the lack of
data on this specific point in the literature. The model-
ling approach used is largely in line with previously
published models in COPD. However, despite recent
recommendations, costs related to comorbidities and
some adverse effects could not be included for IND/
GLY and SFC separately due to lack of corresponding
data [15]. While the most significant and relevant ad-
verse events (exacerbations and pneumonia) were in-
cluded in the model as reported in the FLAME study
[8], other adverse events were omitted as the rates were
small and similar between the two treatment groups
while corresponding costs are low. Thus their inclusion
would not meaningfully inform the cost-effectiveness
analysis. Lastly, the study selected the Swedish implicit
threshold of €55,000 (dependent on the unmet need
and severity of the disease), for which no official refer-
ence is available.
Since the applicability of findings from a controlled
environment to real-world settings is uncertain
hence future research is recommended to follow-up
clinical and economic implications of these findings
in real life.
In patients with moderate to very severe COPD,
LABA/ICS fixed-dose combination is known to reduce
the frequency of COPD exacerbations [33, 34], and it is
also no doubt that some patients may actually benefit
from the addition of ICS. However, an indiscriminate
and long-term use of ICS in these patients may expose
them to an increased risk of developing pneumonia
leading to increased associated healthcare costs [35].
Therefore, as recommended by GOLD, most patients
with moderate to very severe airflow limitation and a
history of exacerbations should be treated with LABA/
LAMA combination before using LABA/ICS.
Until now, the cost-effectiveness of LABA/LAMA
combination vs. LABA/ICS combination in COPD
population with moderate to very severe airflow limi-
tation and ≥1 exacerbation in the preceding year was
uncertain. This study provides an answer to this so far
unaddressed question, showing that from a health eco-
nomic perspective, IND/GLY is not only cost-effective
but should be the preferred treatment option com-
pared to SFC in COPD patients with moderate to very
severe airflow limitation and ≥1 exacerbation in the
preceding year.
Conclusion
Under the current WTP threshold in Sweden, IND/
GLY is a cost-effective treatment compared with SFC
in COPD patients with mMRC dyspnea grade ≥ 2,
moderate to very severe airflow limitation, and a his-
tory of exacerbations. Cost savings were observed with
respect to reduction in exacerbation and pneumonia
costs, and superior efficacy in terms of reduced rate of




























Fig. 3 Net monetary benefit analysis for subgroups. Figure notes: *Severity of airflow limitation based on 2011–2014 GOLD criteria; ^Based on
2015 GOLD staging system. GOLD: global initiative for chronic obstructive lung disease classification
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pneumonia. Sensitivity analyses performed considering key
parameters also confirm the results for their robustness.
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